BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37633404)

  • 1. Apolipoprotein-mimetic nanodiscs reduce lipid accumulation and improve liver function in acid sphingomyelinase deficiency.
    Halseth TA; Correia AB; Schultz ML; Fawaz MV; Kuiper EQ; Kumaran P; Dorsey KH; Schuchman EH; Lieberman AP; Schwendeman A
    Nanomedicine; 2023 Sep; 53():102705. PubMed ID: 37633404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
    Syed YY
    Clin Drug Investig; 2023 May; 43(5):369-377. PubMed ID: 37133675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
    Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
    Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency.
    Gaudioso Á; Jiang X; Casas J; Schuchman EH; Ledesma MD
    Cell Death Dis; 2023 Apr; 14(4):248. PubMed ID: 37024473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Dietary Choline Uptake in a Mouse Model of Acid Sphingomyelinase Deficiency.
    Gaudioso Á; Moreno-Huguet P; Casas J; Schuchman EH; Ledesma MD
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases.
    Cassiman D; Packman S; Bembi B; Turkia HB; Al-Sayed M; Schiff M; Imrie J; Mabe P; Takahashi T; Mengel KE; Giugliani R; Cox GF
    Mol Genet Metab; 2016 Jul; 118(3):206-213. PubMed ID: 27198631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
    Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
    Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly.
    Patel H; Ding B; Ernst K; Shen L; Yuan W; Tang J; Drake LR; Kang J; Li Y; Chen Z; Schwendeman A
    Int J Nanomedicine; 2019; 14():3069-3086. PubMed ID: 31118623
    [No Abstract]   [Full Text] [Related]  

  • 9. Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
    Pulikottil-Jacob R; Ganz ML; Fournier M; Petruski-Ivleva N
    Adv Ther; 2023 May; 40(5):2234-2248. PubMed ID: 36897522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
    Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
    Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency.
    Kubaski F; Burlina A; Pereira D; Silva C; Herbst ZM; Trapp FB; Michelin-Tirelli K; Lopes FF; Burin MG; Brusius-Facchin AC; Netto ABO; Poletto E; Bernardes TM; Carvalho GS; Sorte NB; Ferreira FN; Perin N; Clivati MR; de Santana MTS; Lobos SFG; Leão EKEA; Coutinho MP; Pinos PV; Santos MLSF; Penatti DA; Lourenço CM; Polo G; Giugliani R
    Orphanet J Rare Dis; 2022 Nov; 17(1):407. PubMed ID: 36348386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid Sphingomyelinase Deficiency Type B Patient-Derived Liver Organoids Reveals Altered Lysosomal Gene Expression and Lipid Homeostasis.
    Gomez-Mariano G; Perez-Luz S; Ramos-Del Saz S; Matamala N; Hernandez-SanMiguel E; Fernandez-Prieto M; Gil-Martin S; Justo I; Marcacuzco A; Martinez-Delgado B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).
    McGovern MM; Avetisyan R; Sanson BJ; Lidove O
    Orphanet J Rare Dis; 2017 Feb; 12(1):41. PubMed ID: 28228103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France.
    Mauhin W; Borie R; Dalbies F; Douillard C; Guffon N; Lavigne C; Lidove O; Brassier A
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).
    Wasserstein M; Dionisi-Vici C; Giugliani R; Hwu WL; Lidove O; Lukacs Z; Mengel E; Mistry PK; Schuchman EH; McGovern M
    Mol Genet Metab; 2019 Feb; 126(2):98-105. PubMed ID: 30514648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.
    Thurberg BL; Diaz GA; Lachmann RH; Schiano T; Wasserstein MP; Ji AJ; Zaher A; Peterschmitt MJ
    Mol Genet Metab; 2020; 131(1-2):245-252. PubMed ID: 32620536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
    Wasserstein MP; Diaz GA; Lachmann RH; Jouvin MH; Nandy I; Ji AJ; Puga AC
    J Inherit Metab Dis; 2018 Sep; 41(5):829-838. PubMed ID: 29305734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up.
    Lipiński P; Kuchar L; Zakharova EY; Baydakova GV; Ługowska A; Tylki-Szymańska A
    Orphanet J Rare Dis; 2019 Feb; 14(1):55. PubMed ID: 30795770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis.
    Cappellini MD; Motta I; Barbato A; Giuffrida G; Manna R; Carubbi F; Giona F
    Eur J Intern Med; 2023 Feb; 108():81-84. PubMed ID: 36443133
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.